Myriad Genetics Inc (MYGN) is a publicly traded Healthcare sector company. As of September 9, 2026, MYGN trades at $3.10 with a market cap of $305.12M and a P/E ratio of -2.68. MYGN moved +0.00% today. Year to date, MYGN is -48.29%; over the trailing twelve months it is -53.98%. Its 52-week range spans $2.74 to $15.47. Analyst consensus is sell with an average price target of $2.95. Rallies surfaces MYGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Myriad Genetics Inc (MYGN) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. MYGN moved +0.00% today. Analyst consensus is sell.
| Metric | Value |
|---|---|
| Price | $3.10 |
| Market Cap | $305.12M |
| P/E Ratio | -2.68 |
| EPS | $-1.18 |
| Dividend Yield | 0.00% |
| 52-Week High | $15.47 |
| 52-Week Low | $2.74 |
| Volume | 90.39K |
| Avg Volume | 0 |
| Revenue (TTM) | $806.60M |
| Net Income | $-112.60M |
| Gross Margin | 68.83% |
7 analysts cover MYGN: 0 strong buy, 0 buy, 4 hold, 3 sell, 0 strong sell. Consensus rating is sell. Average price target: $2.95.